Company intelligence / Profile preview

BTI Biotechnology Institute

Vitoria-Gasteiz, Álava, Spain

Ownership: Private
Employees: ~300
Development stage: Preclinical

Overview

BTI Biotechnology Institute is a global leader in regenerative medicine and oral implantology, with its proprietary PRGF – ENDORET® platform widely used across multiple medical specialties. The company’s products are commercialized internationally, with strong clinical adoption but no traditional drug pipeline or staged clinical trials as seen in pharma companies. Its solutions are supported by translational research and numerous patents.

Therapeutic areas: PulmonologyOtherDermatologyCardiovascularOphthalmology
Modalities: DeviceBiologic (specifically, plasma rich in growth factors/PRGF technology)
Industry: Implantable Medical Devices

Partnerships

No major pharmaceutical partnerships publicly listed; focus is on direct commercialization and academic collaborations.

Beyond the preview

Go deeper on BTI Biotechnology Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BTI Biotechnology Institute.

Explore the full profile